Lupin has entered into an exclusive licensing agreement with Valorum Biologics for its biosimilar Armlupeg™ (pegfilgrastim-unne) in the United States. Under the agreement, Valorum will handle the commercialization and distribution, while Lupin will be responsible for manufacturing and supply. Lupin will receive an upfront license fee and a royalty on net sales. This collaboration aims to expand access to affordable treatment options for patients undergoing chemotherapy.
Licensing Agreement Overview
Lupin and Valorum Biologics have reached an exclusive licensing agreement for Lupin’s biosimilar Armlupeg™ (pegfilgrastim-unne) within the United States. This agreement, announced on December 4, 2025, will leverage Valorum’s expertise in biosimilar commercialization and Lupin’s manufacturing capabilities.
Key Terms of the Agreement
Under the terms, Valorum will manage the commercialization and distribution of Armlupeg™ in the U.S. market. Lupin will be responsible for the manufacturing and supply of the product. The financial structure includes an upfront license fee to Lupin and a royalty payment based on net sales. This partnership is designed to bring Armlupeg™ to patients in the U.S., providing a more accessible and affordable treatment option.
Strategic Rationale
The collaboration with Valorum aims to broaden the availability of cost-effective treatment alternatives for individuals undergoing chemotherapy. Lupin emphasizes its dedication to enhancing patient results and ensuring high-quality biosimilars are accessible. Valorum highlights its track record in specialty markets, with expectations to gain a substantial market share.
About Armlupeg™
Pegfilgrastim-unne is prescribed to shorten the duration of neutropenia and lower the incidence of febrile neutropenia in patients undergoing chemotherapy.
Source: BSE